89bio, Inc. (NASDAQ:ETNB) Citi’s Biopharma Back to School Conference September 3, 2025 11:15 AM EDT
Company Participants
Rohan Palekar – CEO & Director
Conference Call Participants
Geoffrey Meacham – Citigroup Inc., Research Division
Presentation
Geoffrey Meacham
Managing Director
So welcome to the next session of the Citi Biopharma back-to-school event. So my name is Geoff Meacham. I’m the senior biopharma analyst. I have my team with me as well. Our next session is 89bio, and we have Rohan Palekar, CEO; and Ryan Martins, CFO. So guys, welcome. Thank you for coming.
Rohan Palekar
CEO & Director
Great to be here, Geoff. Good to see you again.
Question-and-Answer Session
Geoffrey Meacham
Citigroup Inc., Research Division
Good to see you. Let’s just kick it off with a bit of a kind of discussion of the MASH space, all the commercial developments. We’ve had some regulatory developments with respect to noninvasive diagnosis. Give us kind of the state of the market in your view, and then we can get into pegozafermin.
Rohan Palekar
CEO & Director
Sure. So I think, Geoff, it’s a great time to be in the MASH space. I think this was a long time coming, right, where this is a disease state or an indication with a very significant unmet need. And so it’s very encouraging to see we now have 2 drugs which are approved for the treatment of MASH. I think from the interest of the patients, it’s great. And obviously, Rezdiffra last year was the first one and now the recent approval of sema. And I think what it’s going to do really is expand this market because it’s going to drive a lot more of the diagnosis of MASH patients. There’s millions of MASH patients, but most of them are not diagnosed, most of them are not treated. And what we had always heard from physicians is, what am I going to
#89bio #ETNB #Presents #Citis #Biopharma #School #Conference #Transcript